Nanomix Corporation (OTCMKTS:NNMX) announced on August 31, 2022, about appointing Tadd S. Lazarus, M.D., to the Board of Directors as an independent director. Having begun his career at Roche Diagnostics, he has held simultaneous roles in private practice and as Director of Medical and Scientific Affairs, and then as the North American Medical Director for the molecular diagnostics, POC, diabetes, clinical chemistry, and immunology lines of business.
Trading Data
On Wednesday, NNMX stock lost 40.16% to $0.2394 with 4.39K shares, compared to volume of 1.88K shares. The stock moved within a range of $0.2370 – 0.4000 after opening trade at $0.4000.
Nanomix Appoints Industry Veteran Tadd S. Lazarus, M.D., to the Board of Directors
He has also acted as Chief Medical Officer for several organizations, like Achieve Health Management, Inivata Inc., and Clinical Genomics, encompassing biochemistry, medical diagnostics, and patient services arenas. Dr. Thomas Schlumpberger, CEO of Nanomix, is excited to welcome Tadd S. Lazarus on board, as he feels the medical leadership will be of immense value when it comes to commercializing the current Nanomix critical infection assay panel as well as for developing new products on the Nanomix platform, the eLab.
The Nanōmix eLab system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. Test results are available in minutes, at a much lower cost, while the device is portable. Results are accurate and quantitative, comparable in quality to those provided by central lab testing.
Tadd S. Lazarus is equally thrilled to work with the Nanomix team to fully develop the advanced eLab mobile diagnostics testing platform. He has stressed that the objective is to improve Point of Care testing for critical conditions.
Key Quote
“We are extremely pleased to welcome Tadd S. Lazarus, M.D., to the board and leadership of the Company,” said Dr. Thomas Schlumpberger, CEO of Nanomix. “His medical leadership will be of great value for commercializing the current Nanomix critical infection assay panel as well as for developing new products on the Nanomix platform, the eLab.”
